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Abstract
Background: India is an increasingly influential player in the global pharmaceutical market. Key parts of the drug regulatory
system are controlled by the states, each of which applies its own standards for enforcement, not always consistent with
others. A pilot study was conducted in two major cities in India, Delhi and Chennai, to explore the question/hypothesis/
extent of substandard and counterfeit drugs available in the market and to discuss how the Indian state and federal
governments could improve drug regulation and more importantly regulatory enforcement to combat these drugs.
Methodology/Principal Findings: Random samples of antimalarial, antibiotic, and antimycobacterial drugs were collected
from pharmacies in urban and peri-urban areas of Delhi and Chennai, India. Semi-quantitative thin-layer chromatography
and disintegration testing were used to measure the concentration of active ingredients against internationally acceptable
standards. 12% of all samples tested from Delhi failed either one or both tests, and were substandard. 5% of all samples
tested from Chennai failed either one or both tests, and were substandard. Spatial heterogeneity between pharmacies was
observed, with some having more or less substandard drugs (30% and 0% respectively), as was product heterogeneity, with
some drugs being more or less frequently substandard (12% and 7% respectively).
Conclusions/Significance: In a study using basic field-deployable techniques of lesser sensitivity rather than the most
advanced laboratory-based techniques, the prevalence of substandard drugs in Delhi and Chennai is confirmed to be
roughly in accordance with the Indian government’s current estimates. However, important spatial and product
heterogeneity exists, which suggests that India’s substandard drug problem is not ubiquitous, but driven by a subset of
manufacturers and pharmacies which thrive in an inadequately regulated environment. It is likely that the drug regulatory
system in India needs to be improved for domestic consumption, and because India is an increasingly important exporter of
drugs for both developed and developing countries. Some poor countries with high burdens of disease have weak drug
regulatory systems and import many HIV/AIDS, tuberculosis and malaria drugs from India.
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Introduction
India presents definite opportunities and potential perils to
global health in its prolific pharmaceutical industry, for India
is a leading supplier of high quality generic drugs throughout
the world, but it is also a leading source of counterfeit drugs
[1].
Substandard and counterfeit drugs have grave consequences for
public health. Drugs with too little or no active ingredient can
cause patient death and lead to the development of drug
resistance. Resistance at the population level renders legitimate
drugs and even entire classes of drugs less effective, even for
patients who did not previously take poor-quality drugs.
India has a self-admitted problem of manufacturing unreliable
drugs. In 2002, the World Health Organisation (WHO) reported
that Indian pharmaceutical manufacturers themselves estimated
20% of drugs in major Indian-city markets were substandard or
illegal [2]. Similarly, the Indian government estimates that
counterfeit drugs account for 0.34% of the total pharmaceutical
market and substandard drugs account for 9.34% [3]. These data
are based on samples tested by the state authorities between 1995
and 2003; the extent of substandard drugs varied from 8.19 to
10.64 percent and counterfeit drugs varied between 0.24 and 0.47
percent [3]. Other evidence suggests that the quality of India’s
drugs has a global impact. In May 2008, some of the authors
published a study assessing the quality of antimalarial drugs in
Africa [4]. The study found that 35% of antimalarial drugs sold in
private shops and pharmacies in six major African cities failed
basic quality control tests [4]. 31% of the samples purportedly of
Indian origin were found to be substandard.
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drugs, the Indian government commissioned an expert committee
under Dr. R.A. Mashelkar to examine the counterfeit drug
problem and to devise a reform of the regulatory system in India.
The Committee’s report identified many failings, but found that
diligence varied markedly between India’s states. For example, 17
of 31 states and united territories that responded had functional
drug testing laboratories, of which only seven were adequately
equipped and staffed [3]. The Committee recommended upgrad-
ing India’s regulations and regulatory bodies to meet international
standards, to include a National Drug Authority.
The WHO recommends that each country have a ‘‘central
coordinating body with overall responsibility and accountability
for all aspects of drug regulation for the entire country [5].’’ The
creation of a National Drug Authority has been proposed several
times in India but has yet to be enacted.
In 2004, drug-industry analysts estimated that with a compound
annual growth rate between 7 and 10 percent, India’s pharma-
ceutical industry would be worth between $6 and $7 billion in
2008. Given the increasing importance of India as a global
supplier of drugs and active pharmaceutical ingredients for
treatment of all diseases, it is important to improve certainty
about the quality of drugs manufactured in India.
Randomly selected samples were collected from randomly
chosen pharmacies scattered in and around Delhi and Chennai.
Samples of the following drugs listed on the WHO Model List of
Essential Medicines were procured: chloroquine, ciprofloxacin,
erythromycin, isoniazid and rifampicin. This paper assesses the
quality of a small selection of these primarily domestically-
produced drugs on sale in pharmacies in Delhi and Chennai in
an attempt to determine the prevalence of substandard drugs
available to city residents. A total of 541 random samples procured
from 52 pharmacies were assessed using basic field screening
techniques for drug quality.
Results
The drugs procured in this study were readily available over-
the-counter without a prescription in Delhi and Chennai
pharmacies, including all anti-infectives shown in Table 1.
Samples from 281 treatment packs collected from Delhi
pharmacies were tested in duplicate in July 2008, comprising 50
ciprofloxacin, 56 chloroquine, 61 erythromycin, 48 isoniazid and
66 rifampicin. Having recorded solely the better-performing
sample in the duplicate pair, which is a generous assumption that
may understate the incidence of poor drug quality, 12% (34/281)
of tested samples failed thin-layer chromatography (TLC) and/or
disintegration tests. The breakdown of failures is as follows: 0.7%
(2/281) failed only disintegration tests, 0.4% (1/281) failed only
TLC, and 11% (31/281) failed both TLC and disintegration tests
(See Table 1). 10% of ciprofloxacin, 9% of chloroquine, 13% of
erythromycin, 17% of isoniazid and 12% of rifampicin failed one
or more tests.
Samples from 260 treatment packs collected from Chennai
pharmacies were tested in duplicate in March 2009, comprising 53
ciprofloxacin, 63 chloroquine, 56 erythromycin, 36 isoniazid and
52 rifampicin. Having again recorded the better-performing
sample in the duplicate pair, 5% (12/260) of tested samples failed
TLC and/or disintegration tests. The breakdown of failures is as
follows: 0.4% (1/260) failed only disintegration tests, 2% (6/260)
failed only TLC, and 2% (5/260) failed both TLC and
disintegration tests (See Table 1). 6% of ciprofloxacin, 5% of
chloroquine, 2% of erythromycin, 6% of isoniazid and 6% of
rifampicin failed one or more tests.
In total, 541 samples were collected from pharmacies in Delhi
and Chennai, with 8.5% (46/541) of tested samples failing TLC
and/or disintegration tests.
The authors did not conduct forensic analysis of the drugs to
determine whether they were substandard or counterfeit, as results
of previous attempts to collect valid samples and batch information
Table 1. Testing results by drug type and location for TLC and disintegration.
Number
failing TLC
Number failing
disintegration
Number failing TLC
or disintegration
Number
tested
Percent failing TLC
or disintegration
Ciprofloxacin Delhi 5 5 5 50 10%
Chennai 3 1 3 53 6%
Combined Total 8 6 8 103 8%
Chloroquine Delhi 5 5 5 56 9%
Chennai 3 1 3 63 5%
Combined Total 8 6 8 119 7%
Erythromycin Delhi 8 8 8 61 13%
Chennai 1 1 1 56 2%
Combined Total 9 9 9 117 8%
Isoniazid Delhi 6 8 8 48 17%
Chennai 1 1 2 36 6%
Combined Total 7 9 10 84 12%
Rifampicin Delhi 8 7 8 66 12%
Chennai 3 2 3 52 6%
Combined Total 11 9 11 118 9%
TOTAL Delhi 32 33 34 281 12%
Chennai 11 6 12 260 5%
Combined 43 39 46 541 8.5%
doi:10.1371/journal.pone.0006003.t001
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successful. However, fewer than 4% (11/281) of samples collected
in Delhi had zero active ingredients and only two samples
collected in Chennai had very low concentrations of active
ingredients, both of which are indicators of counterfeit prove-
nance. Assuming the country of origin stated on the drug
packaging was correct, 97% (524/541) of tested samples were
manufactured in India, of which 8% (42/524) failed the above
quality control tests. Of these, 21% (9/42) had zero or very low
concentrations of active ingredients. 3% (17/541) of tested samples
(all from Delhi) were labeled as manufactured in the United States,
of which 23.5% (4/17) failed basic quality control tests. All four
U.S. samples that failed one or more tests had zero active
ingredients, suggesting they could be counterfeit.
Of the 26 pharmacies sampled in Delhi, five pharmacies had no
failures, while seven had from 20 to 30 percent failures (See
Figure 1); these seven pharmacies also supplied 10 of the 11
samples found to contain zero active ingredients. Of the 26
pharmacies sampled in Chennai, 16 pharmacies had no failures
and none of the pharmacies sampled had failures above 20% (See
Figure 1).
Given the small sample size in this study, similar studies of the
same drugs from other cities in other states would allow an
assessment of whether those states with better regulatory
environments and/or testing regimes have better quality drugs.
Further analysis of the behavior of pharmacists, notably their drug
procurement practices, is also warranted, given the variation in
drug quality found from different pharmacies around Delhi and
Chennai.
Discussion
According to the World Malaria Report 2008, there were an
estimated 10.6 million cases of malaria in India in 2006 [6].
Chloroquine is still the main treatment for uncomplicated malaria
in India. The WHO ranks India first in terms of total numbers of
cases of tuberculosis (TB). In 2007, there were more than 1.9
million new cases of TB in India [7]. Isoniazid and rifampicin are
considered powerful first line drugs for treatment of TB.
At a 12% failure rate, the quality of drugs in peri-urban
pharmacies around Delhi is slightly worse than the Indian
government’s estimate (roughly 10%) and better than that
estimated by the Indian pharmaceutical industry, as reported to
the WHO. The quality of drugs in pharmacies around Chennai is
slightly better, with only a 5% failure rate. Although the sample
sizes are too small to make broad conclusions and/or generaliza-
tions about the quality of essential drugs in India, they provide at
least one reasonable scenario of the cities sampled. The failures
could be the result of deliberate counterfeiting, or substandard
production, transport or storage. The authors discussed these
results with several local counterfeit drug investigators. The
conclusions of these discussions were as follows: The wide
variation in failure rates among pharmacies (See Figure 1) suggests
that most pharmacists are buying good quality drugs and storing
them properly. However, some pharmacists are either buying,
wittingly or unwittingly, substandard drugs, expired drugs that
have had their packaging possibly re-stamped with new expiry
dates, or are incapable or unwilling to store drugs correctly.
The 12% and 5% failure rates in Delhi and Chennai
respectively are perhaps lower than expected, given that some
WHO-reported data indicates it to be higher [2]. This variation
calls for a system of enforcement to maintain a certain minimum
quality criteria. Given the heavy burden of TB and malaria in the
country, it is pertinent that high quality drugs be made available to
residents. A similar system for exporting drugs should also be in
place.
The failure rates observed in this study could be good news,
demonstrating improved performance driven by the Indian
authorities in response to increased awareness of the regulatory
gaps as revealed by the Mashelkar Report in 2003. However, it
should be noted that the Indian government has called upon
committees in the past to review the regulatory system and make
recommendations for its improvement but ‘‘these recommenda-
tions have been implemented by the Government to some extent,
but the core issues have remained unresolved [3].’’ The
improvement in failure rates could also be the result of individuals,
such as the recent Indian Health Minister, Anbumani Ramadoss
from Tamil Nadu state (capital Chennai), who has championed
Figure 1. Percentage of tested samples failing TLC or disintegration by number of pharmacies sampled in Delhi and Chennai (all
pharmacies with fewer than 5% failures actually had zero failures).
doi:10.1371/journal.pone.0006003.g001
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the better performance of Chennai-sourced drugs in this study.
Sampled pharmacies were located in urban and peri-urban
areas of Delhi and Chennai, which have both higher wealth
(double the national average in Delhi) and more tightly enforced
regulation compared with more rural areas. Regardless, a 12% or
5% failure rate of essential drugs poses a significant threat to the
respective health of Delhi and Chennai residents, and if the results
are indicative of the country as a whole, there is an even greater
danger to far more people. Assuming all cases of malaria and TB
were treated, even a 1% failure rate would mean over 100,000
patients would receive substandard drugs. If the failure rates
observed in this study were indicative of the country as a whole,
then just over a million patients would access substandard drugs
for just these two diseases. This extrapolation is a likely scenario if
this problem is not addressed.
Why are substandard drugs prevalent in India? The Mashelkar
Report of 2003 noted, ‘‘the problems in the regulatory system in
the country were primarily due to inadequate or weak drug
control infrastructure at the State and Central level, inadequate
testing facilities, shortage of drug inspectors, non-uniformity of
enforcement, lack of specially trained cadres for specific regulatory
areas, non-existence of data bank and nonavailability of accurate
information [3].’’ In addition, the division of labor between the
central and state regulatory agencies creates inconsistencies in
regulatory requirements and policies across the country. Individual
states are responsible for licensing and monitoring domestic drug
manufacturers for quality, and pursuing legal action against
offenders. This federal structure means that India lacks national
norms for drug quality, and that most of the quality policing is
done at state level without uniformity of action. This means a
manufacturer producing substandard drugs could receive approval
in a state with weak controls, and its drugs could be sold anywhere
in the country.
Other shortcomings of India’s regulatory system include poor
enforcement and outdated legislation. Legal proceedings are ‘‘far
too complicated and lengthy; the process moves slowly and the
conviction rate is low [3].’’ The 1940 Drugs and Cosmetics Act,
which governs drug production and sale in India, ‘‘contains
various provisions for effective punitive action against manufac-
turers and distributors [3].’’ For adulterated drugs that likely
caused death or bodily harm, the Act’s lack of specificity has led to
its under-utilization.
Additionally, there are too few drug inspectors in India, while
the number of licensed manufacturing and selling premises
increases exponentially. Pharmacists are not required to register
with professional bodies or state boards and do not need to
continue education after their initial qualification. Furthermore,
there is a strong culture of self-prescription in the country, enabled
by pharmacists willing to sell drugs without a prescription.
There are some important ramifications for foreign buyers of
Indian drugs. If within India’s own borders, and in relatively
prosperous cities (Delhi and Chennai), a proportion (12% and 5%
respectively) of drugs are substandard for various reasons, an
assumption of safety is probably premature for at least some of the
drugs that India exports. While developed nations provide strict
import quality controls, probably screening out suspect products,
this is not the case for most of the developing world. At present,
Indian state drug regulatory authorities issue export licenses as well
as a Certificate of Pharmaceutical Product to facilitate such trade.
In all probability this is insufficient government oversight. Dora
Akunyili, former Director General of Nigeria’s National Agency
for Food and Drug Administration and Control, routinely
complained about drugs coming into Nigeria from India and
banned at least 25 Indian drug companies from exporting to
Nigeria [8].
The Indian government should lead an effort to harmonize
regulatory requirements across states and consolidate regulatory
functions, as recommended by the WHO. It should also increase
penalties for those involved in the sale of substandard products as
recommended by the Mashelkar Committee. It could also consider
requiring that all drug manufacturers receive licenses from the
central government, even while allowing states with sufficient
regulatory capacity to continue licensing sales establishments.
This pilot study calls for a larger study to explore the extent of
the availability of substandard and counterfeit drugs in the market.
It calls for an investigation of pharmacies located in different parts
of the country - rural, semi-urban, peri-urban - where the problem
may be more rampant due to less stringent drug quality
enforcement. It also calls for an internal Indian review of the
counterfeit drug problem to tackle the TB, HIV/AIDS and
malaria epidemics in the country.
Materials and Methods
The simple sampling protocol was developed in line with
previously published research [4,9]. Indian nationals from Delhi
and Chennai posed as customers and made drug purchases from
storefront pharmacies located inmiddle-class areas ofeach city.The
‘‘customers’’ were instructed to stay within a single neighborhood
and to select pharmacies at first sight on a random walk, and were
blind as to the purpose for which they were collecting samples.
Samples were obtained in June 2008 from 26 randomly selected
private pharmacies in urban and peri-urban areas of Delhi (the
capital located in northern India). Samples were also obtained in
March 2009 from 26 randomly selected private pharmacies in
urban and peri-urban areas of Chennai (the largest city in southeast
India). ‘‘Customers’’ purchased a sample lot of an antimalarial
(chloroquine, which remains the norm for treating Plasmodium vivax
malaria in Delhi and Chennai), two antibiotics (ciprofloxacin and
erythromycin) and two antimycobacterials (isoniazid and rifampi-
cin) without a prescription. All of these drugs are included on the
WHOModelListofEssentialMedicines.Treatmentpacksincluded
drugs sold in the manufacturer’s original packaging as well as those
distributed loose, often in paper bags. 2% of collected samples were
sold loose with roughly the same quality performance (one failure
out of ten samples tested) as those in blister packs. Once purchased,
all drugs were stored at ambient temperature, with low humidity
and no sunlight – until testing. Tests were completed within 40 days
of sample collection.
The Global Pharma Health Fund e.V. Minilab was used to run
semi-quantitative thin-layer chromatography and disintegration
tests on each sample to determine the presence and relative
concentration of active ingredients [10]. The MinilabH protocols
award products a ‘‘pass’’ for TLC if 80% or more of the labeled
active ingredient(s) is present. Samples were also tested to see if
they disintegrated in water at 37uC in less than 30 minutes. Each
test was run in duplicate, with the generous assumption that the
result more consistent with the reference was recorded. Quality
control of the Minilab was performed daily prior to drug testing
and consisted of performing TLC on Minilab-reference samples
for the five drug classes being analyzed. In addition, Minilab
reagents were quality control tested using reference samples when
a new lot was introduced.
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